Commentary on Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ, Department of Urology and Biochemistry, Mayo Clinical College of Medicine, Rochester, MN

Research output: Contribution to journalShort survey

Abstract

The standard systemic treatment for prostate cancer (PCa) is androgen ablation, which causes tumor regression by inhibiting activity of the androgen receptor (AR). Invariably, PCa recurs with a fatal androgen-refractory phenotype. Importantly, the growth of androgen-refractory PCa remains dependent on the AR through various mechanisms of aberrant AR activation. Here, we studied the 22Rv1 PCa cell line, which was derived from a CWR22 xenograft that relapsed during androgen ablation. Three AR isoforms are expressed in 22Rv1 cells: a full-length version with duplicated exon 3 and two truncated versions lacking the COOH terminal domain (CTD). We found that CTD-truncated AR isoforms are encoded by mRNAs that have a novel exon 2b at their 3′ end. Functionally, these AR isoforms are constitutively active and promote the expression of endogenous AR-dependent genes, as well as the proliferation of 22Rv1 cells in a ligand-independent manner. AR mRNAs containing exon 2b and their protein products are expressed in commonly studied PCa cell lines. Moreover, exon 2b-derived species are enriched in xenograft-based models of therapy-resistant PCa. Together, our data describe a simple and effective mechanism by which PCa cells can synthesize a constitutively active AR and thus circumvent androgen ablation.

Original languageEnglish (US)
Pages (from-to)231-232
Number of pages2
JournalUrologic Oncology: Seminars and Original Investigations
Volume27
Issue number2
DOIs
StatePublished - Mar 1 2009

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint Dive into the research topics of 'Commentary on Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ, Department of Urology and Biochemistry, Mayo Clinical College of Medicine, Rochester, MN'. Together they form a unique fingerprint.

  • Cite this